Aquestive Therapeutics, Inc. (AQST) - Dilution Analysis

10-Q filing | 122.6M shares outstanding

10-Q filing | 110.6M shares outstanding

10-Q filing | 99.3M shares outstanding

10-Q filing | 95.5M shares outstanding

10-K filing | 98.9M shares outstanding

10-Q filing | 91.1M shares outstanding

10-Q filing | 90.9M shares outstanding

10-Q filing | 91.0M shares outstanding

8-K filing: Aquestive Therapeutics, Inc. completed a public offering on March 22, 2024, selling 16,666,667 shares of common stock at $4.50 per share, and on April 22, 2024, the Underwriters purchased 559,801 additional shares to cover over-allotments, bringing the total gross proceeds to approximately $77.5 million. ($77.52M proceeds)

S-3 filing: Aquestive Pharmaceuticals, Inc. files an S-3 form to offer up to $250,000,000 of common stock, preferred stock, and debt securities from time to time.

8-K filing: Aquestive Therapeutics, Inc. entered into an underwriting agreement for a public offering of 16,666,667 shares of common stock at $4.50 per share, with an option for underwriters to purchase an additional 2,500,000 shares, expecting net proceeds of approximately $69.8 million. ($69.8M proceeds)

10-K filing | 73.3M shares outstanding

10-Q filing | 64.7M shares outstanding

S-3 filing: This prospectus relates to the resale of up to 2,750,000 shares of Aquestive Therapeutics, Inc. common stock by the selling stockholder.

10-Q filing | 61726.7M shares outstanding

8-K filing: Aquestive Therapeutics executed an agreement to issue 5,000,000 shares of common stock upon the exercise of existing warrants at $0.96 per share, receiving gross proceeds of $4,800,000.00 and issuing new warrants to purchase up to 2,750,000 shares of common stock. ($8.34M proceeds)

10-Q filing | 55.6M shares outstanding

10-K filing | 55.9M shares outstanding

10-Q filing | 53.4M shares outstanding

8-K filing: Aquestive Therapeutics, Inc. granted an inducement equity award under the 2022 Equity Inducement Plan to Kenneth Truitt, M.D., consisting of non-qualified options to purchase 100,000 unregistered shares of the Company's common stock, effective on September 6, 2022.

10-Q filing | 53.4M shares outstanding

10-Q filing | 41.5M shares outstanding

8-K filing: Aquestive Therapeutics, Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, allowing the Company to sell up to $40,000,000 of shares of its common stock over a 36-month period; also issued 225,310 shares to Lincoln Park as consideration for its commitment.

10-K filing | 38.1M shares outstanding

10-Q filing | 39.2M shares outstanding

10-Q filing | 38.9M shares outstanding

10-Q filing | 33.6M shares outstanding

S-3 filing: Aquestive Pharmaceuticals, Inc. may offer up to $250,000,000 of any combination of common stock, preferred stock and debt securities from time to time.

10-K filing | 33.6M shares outstanding

S-3 filing: This S-3 filing registers for resale up to 143,000 shares of common stock issuable upon the exercise of warrants and up to 16,000 shares of common stock held by selling stockholders.

8-K filing: Aquestive Therapeutics, Inc. received $50.0 million in gross proceeds pursuant to its Purchase and Sale Agreement with MAM Pangolin Royalty, LLC, completed the repurchase of $22.5 million aggregate principal amount of Notes, issued $4.0 million aggregate principal amount of additional Notes, made an additional $2.25 million cash payment to certain holders of the Notes, and issued warrants to purchase up to 143,000 shares of the Company's common stock.

10-Q filing | 33.6M shares outstanding

8-K filing: Aquestive Therapeutics, Inc. entered into a First Supplemental Indenture to its Base Indenture, issuing an additional $4.0 million aggregate principal amount of Notes, agreeing to repurchase $22.5 million aggregate principal amount of Notes, and issuing warrants to purchase up to 857,000 shares of common stock.

10-Q filing | 33.6M shares outstanding

10-Q filing | 33.6M shares outstanding

10-K filing | 33.6M shares outstanding